Vincenzi1 R, Trower M, Duggal A, et al. - A randomized, placebo-controlled phase II trial was designed to assess the efficacy of orvepitant (10 or 30 mg given once daily, orally for 4 weeks), a neurokinin-1 receptor antagonist, compared with placebo in reducing the intensity of epidermal growth factor receptor inhibitor (EGFRI)-induced intense pruritus. The study included a total of 44 individuals aged ≥ 18 years receiving an EGFRI for a histologically confirmed malignant solid tumour and experiencing moderate or intense pruritus after EGFRI treatment from 15 hospitals in Italy and five hospitals in the UK. Orvepitant was found to be safe and well-tolerated. There was no difference in NRS score between the orvepitant and placebo groups at the week 4 primary endpoint. In addition, several explanations for this result are possible.